A Phase 2 interventional study of VP-102 with applicator in Molluscum Contagiosum, sponsored by Verrica Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-11.
Sponsored by Verrica Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Molluscum Contagiosum with a site in United States — none open to participants now, none under way, none of them phase 3. Molluscum Contagiosum · United States.
Among the 15 studies in Molluscum Contagiosum with a site in United States, this one is the 10th largest by enrollment, is one of 3 that started in 2017, is one of 5 in phase 2, and was the 6th registered.
22 studies on the registry are indexed under Molluscum Contagiosum; none are open to participants now.
Browse Molluscum Contagiosum studies →None of the 15 studies in Molluscum Contagiosum with a site in United States is open now. The open studies under Molluscum Contagiosum, anywhere →
This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2017.
This study's enrollment of 33 is below the median of 94 across 19 interventional studies indexed under Molluscum Contagiosum.
Median enrollment 100 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 15 have an industry lead sponsor. The 10 most frequent:
Verrica Pharmaceuticals Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Verrica Pharmaceuticals Inc. has 3 studies filed under Molluscum Contagiosum — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Molluscum Contagiosum with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution [0.7% (w/v) cantharidin] (VP-102) when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older. Treatment will continue over the course of 3 additional 21 day intervals allowing for further evaluation of safety, efficacy and impact on quality of life.
This is a Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) cantharidin] in subjects 2 years and older with Molluscum Contagiosum. Up to 40 subjects will be enrolled in the study with the goal of 16 meeting criteria for, and completing all scheduled blood draws outlined in the exposure portion of the trial. Subjects that do not have enough molluscum lesions to participate in the exposure study but do meet all other criteria to participate in the study will be enrolled in the standard treatment group. No more than 16 subjects will complete exposure group activities; up to 16 subjects will be enrolled in the standard treatment group. The additional 8 subjects may be used for replacement patients. At least 3 patients in the exposure group will be from 2-5 years of age. All subjects will receive VP-102 containing 0.7% cantharidin to molluscum lesions every 21 days for a maximum of 4 sessions or until complete clearance.
In the exposure group, blood samples for systemic exposure evaluation will be collected on Day 1, prior to the drug application, and 2 (± 30 minutes), 6 (± 1 hour) and 24 (±3 hours) hours post-application. A dermatological examination will be performed by a qualified investigator quantifying molluscum lesion counts at every study visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.
Combination Product: VP-102 with applicator
This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.
Combination Product: VP-102 with applicator
Subjects will receive treatment to their molluscum contagiosum with VP-102.
The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102.
The primary objective is to determine any potential systemic exposure from a single 24-hour dermal application of VP-102 topical film-forming solution when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older.
Time frame: 24 hours
Measurement of Efficacy - Complete Clearance
Proportion of subjects exhibiting complete clearance of all treated molluscum lesions (baseline and new) on or before Week 12 (EOS).
Time frame: Baseline through EOS Day 84
Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit.
Summaries of \>=90% clearance by visit include clearance at that visit or any earlier visit (cumulative) baseline and ew at the EOS visit.
Time frame: Baseline to EOS Day 84
Percent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit.
Percent reduction of treated molluscum lesions from Baseline Visit at the EOS visit.
Time frame: Baseline to EOS Day 84
Change From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit.
Molluscum Lesions- Change from Baseline visit in the number of treated molluscum lesions at the EOS Day 84 visit
Time frame: Baseline to EOS Day 84
Change From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment
Change from Baseline in quality of life and impact of skin disease as measured by CDLQI assessment, Children's Dermatology Life Quality Index (CDLQI)- Composite Score The CDLQI was a 10-item questionnaire completed by subject/parent to assess skin condition over the previous week. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response: * 3: Very much (or Prevented School, Question 7 only) * 2: Quite a lot * 1: Only a little * 0: Not at all
Time frame: Baseline to EOS Day 84
Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject.
Spread of molluscum to siblings as measured by any new occurrence of molluscum in siblings of the subject.
Time frame: Baseline to EOS Day 84
| Milestone | Exposure Group | Standard Group |
|---|---|---|
| Started | 17 | 16 |
| Completed | 16 | 16 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
The primary objective is to determine any potential systemic exposure from a single 24-hour dermal application of VP-102 topical film-forming solution when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older.
| Participants | Exposure Group |
|---|---|
| Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) Pre-treatment — Yes | 0 |
| Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) Pre-treatment — No | 16 |
| Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 2hr Post Treatment — Yes | 1 |
| Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 2hr Post Treatment — No | 15 |
| Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 6hr Post Treatment — Yes | 0 |
| Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 6hr Post Treatment — No | 16 |
| Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 24hr Post Treatment — Yes | 0 |
| Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 24hr Post Treatment — No | 16 |
Proportion of subjects exhibiting complete clearance of all treated molluscum lesions (baseline and new) on or before Week 12 (EOS).
| Participants | Exposure Group | Standard Group |
|---|---|---|
| Complete Clearance Day 21 | 0 | 3 |
| Complete Clearance Day 42 | 2 | 7 |
| Complete Clearance Day 63 | 4 | 9 |
| Complete Clearance EOS Day 84 | 6 | 10 |
Summaries of \>=90% clearance by visit include clearance at that visit or any earlier visit (cumulative) baseline and ew at the EOS visit.
| Participants | Exposure Group | Standard Group |
|---|---|---|
| >=90% Clearance Day 21 | 0 | 3 |
| >=90% Clearance Day 42 | 5 | 7 |
| >=90% Clearance Day 63 | 8 | 10 |
| >=90% Clearance Day 84 | 12 | 13 |
Percent reduction of treated molluscum lesions from Baseline Visit at the EOS visit.
| percentage change from Baseline | Exposure Group | Standard Group |
|---|---|---|
| Percent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit. | -87.8 ± 21.25 | -93.0 ± 12.93 |
Molluscum Lesions- Change from Baseline visit in the number of treated molluscum lesions at the EOS Day 84 visit
| change in wart count | Exposure Group | Standard Group |
|---|---|---|
| Change From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit. | -39.3 ± 21.98 | -10.7 ± 6.16 |
Change from Baseline in quality of life and impact of skin disease as measured by CDLQI assessment, Children's Dermatology Life Quality Index (CDLQI)- Composite Score The CDLQI was a 10-item questionnaire completed by subject/parent to assess skin condition over the previous week. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response: * 3: Very much (or Prevented School, Question 7 only) * 2: Quite a lot * 1: Only a little * 0: Not at all
| units on a scale change from Baseline | Exposure Group | Standard Group |
|---|---|---|
| Change From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment | 2.71 ± 2.801 | 2.44 ± 4.115 |
Spread of molluscum to siblings as measured by any new occurrence of molluscum in siblings of the subject.
| Participants | Exposure Group | Standard Group |
|---|---|---|
| Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject. | 0 | 0 |
Collected over Baseline to EOS Day 84. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Exposure Group | 0/17 (0%) | 0/17 (0%) | 16/17 (94.1%) |
| Standard Group | 0/16 (0%) | 0/16 (0%) | 13/16 (81.3%) |
| Event | Exposure Group | Standard Group |
|---|---|---|
| PainGeneral disorders | 11/17 | 8/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/17 | 3/16 |
| HeadacheNervous system disorders | 2/17 | 3/16 |
| VomitingGastrointestinal disorders | 1/17 | 3/16 |
| ScarSkin and subcutaneous tissue disorders | 3/17 | 1/16 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/17 | 2/16 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/17 | 1/16 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/17 | 1/16 |
| Paranasal sinus hypersecretionRespiratory, thoracic and mediastinal disorders | 0/17 | 1/16 |
| Respiratory tract congestionRespiratory, thoracic and mediastinal disorders | 0/17 | 1/16 |
ITT Population
| Age, Continuous(years) | Exposure Group | Standard Group | Total |
|---|---|---|---|
| Mean | 6.6 ± 3.45 | 6.8 ± 3.15 | 6.7 ± 3.26 |
| Sex: Female, Male(Participants) | Exposure Group | Standard Group | Total |
|---|---|---|---|
| Female | 7 | 8 | 15 |
| Male | 10 | 8 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Exposure Group | Standard Group | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 17 | 14 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Exposure Group | Standard Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 16 | 14 | 30 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Exposure Group | Standard Group | Total |
|---|---|---|---|
| United States | 17 | 16 | 33 |
| Baseline Number of Molluscum Lesions(molluscum lesions) | Exposure Group | Standard Group | Total |
|---|---|---|---|
| Mean | 47.4 ± 25.69 | 11.6 ± 6.33 | 30.0 ± 26.07 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Jun 2018, 12 months.
Results were first posted in Aug 2021, 3 years 1 month after primary completion. A results delay was requested in Jul 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Verrica Pharmaceuticals Inc.